Results 191 to 200 of about 15,787 (297)

Optimising Connectivity in Deep‐Sea MPA Networks for Nephrops norvegicus Recovery in NW Mediterranean Sea

Ecology and Evolution, Volume 16, Issue 10, October 2026.
In the NW Mediterranean, where the Norway lobster (Nephrops norvegicus) is both ecologically and economically important, larval connectivity in an existing network of Fishery No‐Take Zones was estimated using Lagrangian transport simulation informed by species‐specific habitat models.
Morane Clavel‐Henry, Nixon Bahamon, Miguel López, Jacopo Aguzzi, Joan Navarro, Joan B. Company   +5 more
wiley   +1 more source

Intercalary meristems revisited: from anatomical regions to cell-resolved fate systems. [PDF]

For Res (Fayettev)
Niu S.
europepmc   +1 more source

Effect of Hyaluronic Acid Molecular Weight on Physicochemical and Rheological Properties of Ice Cream

Food Science &Nutrition, Volume 14, Issue 10, October 2026.
We prepared ice cream formulations, including a control with a commercial stabilizer–emulsifier blend at 0.3% and four treatments with 0.3% hyaluronic acid (HA) at different molecular weights (320, 980, 1550, and 2550 kDa), and compared them. Increasing HA molecular weight was associated with increased hardness, improved creaming stability, enhanced ...
Rutvi Joshi, Mahmoud E. A. Hamouda, Prafulla Salunke   +2 more
wiley   +1 more source

Corifollitropin alfa versus daily recombinant FSH for ovarian stimulation in women of advanced maternal age: a cost-minimization analysis in an out-of-pocket setting. [PDF]

Front Reprod Health
Cecchino GN, Carvalho BR, Ramires Y, Bueno RLP, Lucio LA, Santana VP.   +5 more
europepmc   +1 more source

MEK inhibition achieves robust and durable responses in Erdheim–Chester disease

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract Erdheim–Chester disease (ECD) is a rare histiocytic neoplasm characterized by heterogeneous clinical manifestations and limited evidence to guide targeted therapy. While MEK inhibitors (MEKi) are increasingly used, data on their real‐world efficacy, durability, and safety remain incomplete.
Francesco Pegoraro, Félicien Triboulet, Matthias Papo, Francesco Peyronel, Anita Argentieri, Jerome Razanamahery, Ahmed Idbaih, Polyzois Makras, Ofer Shpilberg, Oshrat Hershkovitz‐Rokah, Michael Girschikofsky, Matthew Collin, Kristian Bowles, Satyen H. Gohil, Rodothea Amerikanou, Emmanuel Ledoult, Tanguy Le Scornet, Mathilde de Menthon, Etienne Riviere, Xavier Boulu, Henry Dupuy, Achille Aouba, Stanislas Faguer, Xavier Solanich, Elena Sieni, Stéphane Barete, Chiara Bellino, Alessandro Tomelleri, Corrado Campochiaro, Lorenzo Dagna, Zahir Amoura, Jean‐François Emile, Fleur Cohen‐Aubart, Augusto Vaglio, Julien Haroche   +34 more
wiley   +1 more source

Integrating delivery systems and microenvironmental cues to accelerate clinical translation of cardiac reprogramming. [PDF]

Mater Today Bio
Son B, Park GY, Jeong I, Kim H, Lee J, Joo J, Lee W, Park HH.   +7 more
europepmc   +1 more source

Appropriate ICD Therapies in Primary Prevention: A Propensity‐Matched Comparison of Contemporary and Historic Heart Failure Cohorts

Journal of Arrhythmia, Volume 42, Issue 5, October 2026.
No significant difference in appropriate ICD therapies between treatment eras. Time to first ICD therapy was similar after propensity‐score matching. The result was robust to a sensitivity analysis using an expanded propensity model. Cumulative incidence, accounting for competing risk of death, was also higher.
Inês Ferreira Neves, Guilherme Portugal, Julien Lopes, Ana Rita Teixeira, Pedro Silva Cunha, Bruno Valente, Ana Lousinha, Rita Moreira, Hélder Santos, António Gonçalves, Rui Cruz Ferreira, Mário Martins Oliveira   +11 more
wiley   +1 more source

Assessment of transradicular diffusion of different intracanal medicaments through root dentin and cementum: An <i>in vitro</i> ultraviolet-visible spectrophotometric analysis. [PDF]

J Conserv Dent Endod
Halkai R, Halkai KR, Supriya G.
europepmc   +1 more source

Applying a Pareto‐Based Efficiency Frontier to Inform Value‐Based Pricing for Gaucher Disease Therapies in Brazil

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 10, October 2026.
ABSTRACT Purpose Gaucher disease (GD) requires lifelong high‐cost treatment within the Brazilian Unified Health System (SUS). In Brazil, treatment eligibility and monitoring are defined by Clinical Protocol and Therapeutic Guidelines (PCDT), while pharmaceutical prices are regulated by the Drug Market Regulation Chamber (CMED).
Marcus Carvalho Borin, Ludmila Peres Gargano, Francisco de Assis Acurcio, Juliana Álvares‐Teodoro, Augusto Afonso Guerra Junior   +4 more
wiley   +1 more source

PGM1 deficiency is linked to sarcomeric and mitochondrial dysfunction in patient-derived iPSC-cardiomyocytes. [PDF]

J Transl Med
Radenkovic S, Preston G, Budhraja R, Muffels I, Ligezka A, Staff NP, Hrstka R, Balakrishnan B, Shah R, Verberkmoes S, Shammas I, Bosnyak I, Stiers KM, Lai K, Beamer LJ, Pandey A, Morava E, Kozicz T.   +17 more
europepmc   +1 more source